Novokhatnya A. E., Lobunets O. O., Shapovalova O. E.

Kharkiv Medical Academy of Postgraduate Education, Ukraine

Clinico-genetic issues of gastroenterological pathology development on the background of respiratory diseases

One of the directions of medicine development is the priority of individualization in diagnosis, treatment and prophylaxis of diseases [1, 2], especially concominant [3], which is conducted, significantly, by evaluation of genetic aspects.

Genetic issues of gastroenterological pathology development on the background of respiratory diseases is actual, treating but still not enough discovered problem of modern medicine in general and therapy (gastroenterology, pulmonology) as well.

It has been stated that SPINK1 p. N34S gene variation might be one of possible endogenous factor related to chronic pancreatitis development. The meta-analysis of studies (2007–2015) related to the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis conducted by Di Leo M. et al has confirmed the association between SPINK1 p.N34S gene variation and chronic pancreatitis, together with the fact that an idiopathic etiology needs a better definition by means of genetic analysis [4].

The fact of close interrelation of exogenous and endogenous (genetic) aspects in gastropulmonological pathology development is indirectly represented by the study dedicated to reveal if genetic factors interact with tobacco smoke to modify risk for inflammatory bowel disease in humans and mice [5]. In an analysis of 55 immunochip-wide data sets, they identified 64 single nucleotide polymorphisms whose association with risk for inflammatory bowel disease is modified by tobacco smoking. Gene-smoking interactions were confirmed in mice with disruption of Il10 and Nod2-variants of these genes have been associated with risk for inflammatory bowel disease. Their findings from mice and humans revealed that the effects of smoking on risk for inflammatory bowel disease depend on genetic variants.

Apart of above mentioned, genotyping of 167 inflammatory bowel disease patients using polymerase chain reaction-based methodology and testing for disease genotype-phenotype associations showed that in patients with ileal localization of disease it was more frequent in NOD2 variant carriers. Ileal inflammatory bowel disease was associated with IL-6 GC+CC genotypes, identifying C allele as a possible marker of increased risk for ileal inflammatory bowel disease. In inflammatory bowel disease patients a positive family history for inflammatory bowel disease was related to earlier onset of disease, higher risk for inflammatory bowel disease -related surgery, and appendectomy. Inflammatory bowel disease patients who are TLR4 299Gly carriers are at higher risk for surgery at onset of the disease compared with TLR4 299Asp variant carriers. The presence of granuloma in biopsy specimens was more frequent in patients in whom a diagnosis of inflammatory bowel disease was made during emergency surgery. Multivariate analysis showed that inflammatory bowel disease carriers of the 299Gly allele had a 4.6-fold higher risk for emergency surgery before inflammatory bowel disease diagnosis is established compared with noncarriers, suggesting an aggressive disease course. Granuloma in endoscopic biopsies is detected 5.4-fold more frequently in patients treated surgically at the time of diagnosis. This proved that genetic variants together with epidemiological and clinical data of inflammatory bowel disease patients could potentially be used as predictors of the disease course [6].

Undoubtfully, an important pathophysiological joint role is played by genetic, inflammatory, microbiological issues [7] etc.

Identification of genetic markers of pathology indentifies novel risk group criteria [8].

Conclusions. Thus, clinico-genetic issues of gastroenterological pathology development on the background of respiratory diseases deserves a special attention. Further perspectives should concern investigations of genetic aspects merging gastroenterological and pulmonological pathology development.

References:

1.       A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: a danish multidisciplinary collaboration on prognostic factors and personalised medicine / V. Andersen, U. Holmskov, S. B. Sørensen [et al.] // Nutrients. — 2017. — Vol. 9, No. 5. — pii: E499. doi: 10.3390/nu9050499.

2.       Stephens M. C. Individualized medicine in gastroenterology and hepatology / M. C. Stephens, L. A. Boardman, K. N. Lazaridis  // Mayo Clin Proc. — 2017. — Vol. 92, No. 5. — P. 810-825 doi: 10.1016/j.mayocp.2017.03.002.

3.       Multimorbidity as an important issue among women: results of a gender difference investigation in a large population-based cross-sectional study in West Asia / M. Alimohammadian, A. Majidi, M. Yaseri [et al.] // BMJ Open. — 2017. — Vol. 7, No. 5. — e013548 doi: 10.1136/bmjopen-2016-013548.

4.       Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update / M. Di Leo, M. Bianco, R. A. Zuppardo [et al.] // Dig Liver Dis. — 2017. — pii: S1590-8658(17)30855-1. doi: 10.1016/j.dld.2017.04.023.

5.       Genetic factors interact with tobacco smoke to modify risk for inflammatory bowel disease in humans and mice / P. Yadav, D. Ellinghaus, G. Rémy [et al.] // Gastroenterology. — 2017. — pii: S0016-5085(17)35596-8. doi: 10.1053/j.gastro.2017.05.010.

6.       Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease / S. Dragasevic, B. Stankovic, T. Milosavljevic [et al.] // Eur J Gastroenterol Hepatol. — 2017. — doi: 10.1097/MEG.0000000000000877.

7.       Biancheri P. The relative contributions of the gut microbiome, host genetics, and environment to cytokine responses to microbial stimulation / P. Biancheri, A. J. M. Watson  // Gastroenterology. — 2017. — pii: S0016-5085(17)35546-4. doi: 10.1053/j.gastro.2017.04.037.

8.       A genome-wide association study identifies six novel risk loci for primary biliary cholangitis / F. Qiu, R. Tang, X. Zuo [et al.] // Nat Commun. — 2017. — No. 8. — 14828 doi: 10.1038/ncomms14828.